MedTrace Logo

Adoption of Innovative Approaches to Ensure Continuity of Quality TB Services During COVID-19 Pandemic in Lusaka and Livingstone, Zambia. (Telemedicine in TB)

NCT06883643 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3318

Last updated 2025-03-19

No results posted yet for this study

Summary

Following the negative impact of public health program services including TB services by the COVID-19 Pandemic in 2020, CIDRZ conducted a program evaluation for remote patient follow up for TB treatment and prevention through a differentiated service delivery model (DSD), offering clinical monitoring and psychosocial support while minimizing contact with the health facilities. The project was implemented between February 2022 to March 2023 and was funded through Centers for Disease Control and Prevention's COVID-19 Response International Task Force - CARES funding. While DSD models have been widely adopted in HIV programs , DSD is a relatively new and exciting approach for TB treatment and prevention programs.

Conditions

  • Focus of the Study is to Evaluate DSD Models for Both TB Treatment and TPT Usiing Key Performance Indicators

Interventions

BEHAVIORAL

Differentiated service delivery approach (DSD) in TB treatment and prevention.

Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.

Sponsors & Collaborators

  • Ministry of Health, Zambia

    collaborator OTHER_GOV

  • Centers for Disease Control and Prevention's COVID-19 Response International Task Force - CARES funding

    collaborator UNKNOWN

  • Centre for Infectious Disease Research in Zambia

    lead OTHER

Principal Investigators

  • Mwanza Wa Mwanza, MD · Centre for Infectious Disease Research in Zambia

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-04
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06883643 on ClinicalTrials.gov